61° and Cloudy
Pharmaceutical Firm Pays $1.99 Million to Settle False Claims Act Violations
In a landmark settlement, Caribe Holdings acknowledges receipt of a PPP loan under false pretenses, highlighting scrutiny of COVID-19 relief fraud.
The U.S. Attorney's Office, under the stewardship of Philip R. Sellinger, disclosed a significant settlement with Caribe Holdings Cayman Co. Ltd., a Puerto Rico-based pharmaceutical manufacturer. The settlement resolves allegations of the company’s improper acquisition of a Paycheck Protection Program (PPP) loan, amounting to a substantial $1.99 million repayment to the United States, marking a decisive action against misuse of pandemic relief efforts.
In March 2021, amidst the tumultuous economic downturn caused by the COVID-19 pandemic, Caribe applied for and received a $1.2 million PPP loan. The application process involved certifying eligibility criteria, notably that the entity was not significantly controlled by interests in the People’s Republic of China. Contrary to these assertions, it was revealed that the company did not meet these eligibility requirements, casting a shadow over the integrity of its loan procurement and subsequent forgiveness request.
"The Paycheck Protection Program was designed as a lifeline for small businesses adversely affected by the COVID-19 pandemic, not as a financial loophole for ineligible entities," U.S. Attorney Sellinger remarked, emphasizing the government's commitment to rectifying instances of fraud within these relief programs.
This settlement emanates from a lawsuit under the whistleblower provision of the False Claims Act, demonstrating the critical role of private citizens in unveiling fraudulent activities against federal programs. The relator in this case, identified as GNGH2, Inc., plays a pivotal part in the recovery process, highlighting the collaborative effort between the public and the justice system in safeguarding the integrity of government assistance programs.
Caribe’s willingness to fully cooperate with the investigation and resolution of the allegations was noted, showcasing the potential for corrective measures in the wake of legal scrutiny. This case serves as a cautionary tale and a stern reminder of the legal and financial repercussions awaiting those who seek to exploit federal relief efforts.
The government's persistent efforts to ensure accountability and transparency in the disbursement and utilization of COVID-19 relief funds are embodied in the actions of Assistant U.S. Attorney David V. Simunovich and the Health Care Fraud Unit in Newark. As the fight against pandemic-related fraud continues, the public is urged to report any suspicions of fraud to the Department of Justice’s National Center for Disaster Fraud Hotline, ensuring that relief efforts reach their intended recipients.
